The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results
Identifieur interne : 006424 ( Main/Exploration ); précédent : 006423; suivant : 006425The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results
Auteurs : Coleman [Royaume-Uni] ; K. W. Lange [Royaume-Uni] ; N. P. Quinn [Royaume-Uni] ; A. E. Loper [États-Unis] ; J. V. Bondi [États-Unis] ; M. Hichens [États-Unis] ; S. M. Stahl [Royaume-Uni, États-Unis] ; C. D. Marsden [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 1989.
English descriptors
- KwdEn :
- (+)‐4‐Propyl‐9‐hydroxynaphthoxazine, Administration, Cutaneous, Adult, Antiparkinson Agents (antagonists & inhibitors), Antiparkinson Agents (pharmacokinetics), Dopamine Antagonists, Dopamine agonist, Drug Administration Schedule, Drug Therapy, Combination, Humans, Levodopa (administration & dosage), Middle Aged, Motor Skills (drug effects), On‐off fluctuations, Oxazines (administration & dosage), Oxazines (pharmacokinetics), Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson's disease, Transdermal drug delivery.
- MESH :
- chemical , administration & dosage : Levodopa, Oxazines.
- chemical , antagonists & inhibitors : Antiparkinson Agents.
- chemical , pharmacokinetics : Antiparkinson Agents, Oxazines.
- blood : Parkinson Disease.
- drug effects : Motor Skills.
- drug therapy : Parkinson Disease.
- Administration, Cutaneous, Adult, Dopamine Antagonists, Drug Administration Schedule, Drug Therapy, Combination, Humans, Middle Aged.
Abstract
(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.
Url:
DOI: 10.1002/mds.870040204
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002F27
- to stream Istex, to step Curation: 002F27
- to stream Istex, to step Checkpoint: 004454
- to stream PubMed, to step Corpus: 004F77
- to stream PubMed, to step Curation: 004F77
- to stream PubMed, to step Checkpoint: 004F58
- to stream Ncbi, to step Merge: 004531
- to stream Ncbi, to step Curation: 004531
- to stream Ncbi, to step Checkpoint: 004531
- to stream Main, to step Merge: 009777
- to stream Main, to step Curation: 006424
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title><author><name sortKey="Coleman" sort="Coleman" uniqKey="Coleman" last="Coleman">Coleman</name></author><author><name sortKey="Lange, K W" sort="Lange, K W" uniqKey="Lange K" first="K. W." last="Lange">K. W. Lange</name></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name></author><author><name sortKey="Loper, A E" sort="Loper, A E" uniqKey="Loper A" first="A. E." last="Loper">A. E. Loper</name></author><author><name sortKey="Bondi, J V" sort="Bondi, J V" uniqKey="Bondi J" first="J. V." last="Bondi">J. V. Bondi</name></author><author><name sortKey="Hichens, M" sort="Hichens, M" uniqKey="Hichens M" first="M." last="Hichens">M. Hichens</name></author><author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CDB145AA1E9A01CCC106745F8337B15DA7C6FA44</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/mds.870040204</idno><idno type="url">https://api.istex.fr/document/CDB145AA1E9A01CCC106745F8337B15DA7C6FA44/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F27</idno><idno type="wicri:Area/Istex/Curation">002F27</idno><idno type="wicri:Area/Istex/Checkpoint">004454</idno><idno type="wicri:doubleKey">0885-3185:1989:Coleman:the:antiparkinsonian:actions</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2733705</idno><idno type="wicri:Area/PubMed/Corpus">004F77</idno><idno type="wicri:Area/PubMed/Curation">004F77</idno><idno type="wicri:Area/PubMed/Checkpoint">004F58</idno><idno type="wicri:Area/Ncbi/Merge">004531</idno><idno type="wicri:Area/Ncbi/Curation">004531</idno><idno type="wicri:Area/Ncbi/Checkpoint">004531</idno><idno type="wicri:doubleKey">0885-3185:1989:Coleman R:the:antiparkinsonian:actions</idno><idno type="wicri:Area/Main/Merge">009777</idno><idno type="wicri:Area/Main/Curation">006424</idno><idno type="wicri:Area/Main/Exploration">006424</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results</title><author><name sortKey="Coleman" sort="Coleman" uniqKey="Coleman" last="Coleman">Coleman</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Lange, K W" sort="Lange, K W" uniqKey="Lange K" first="K. W." last="Lange">K. W. Lange</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Psychiatry, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Psychiatry, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Loper, A E" sort="Loper, A E" uniqKey="Loper A" first="A. E." last="Loper">A. E. Loper</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania</wicri:regionArea><wicri:noRegion>U.K. and Pennsylvania</wicri:noRegion></affiliation></author><author><name sortKey="Bondi, J V" sort="Bondi, J V" uniqKey="Bondi J" first="J. V." last="Bondi">J. V. Bondi</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania</wicri:regionArea><wicri:noRegion>U.K. and Pennsylvania</wicri:noRegion></affiliation></author><author><name sortKey="Hichens, M" sort="Hichens, M" uniqKey="Hichens M" first="M." last="Hichens">M. Hichens</name><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania</wicri:regionArea><wicri:noRegion>U.K. and Pennsylvania</wicri:noRegion></affiliation></author><author><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation><affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Merck, Sharp and Dohme Research Laboratories, Harlow, U.K. and Pennsylvania</wicri:regionArea><wicri:noRegion>U.K. and Pennsylvania</wicri:noRegion></affiliation></author><author><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>The Institute of Neurology, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989">1989</date><biblScope unit="vol">4</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="129">129</biblScope><biblScope unit="page" to="138">138</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">CDB145AA1E9A01CCC106745F8337B15DA7C6FA44</idno><idno type="DOI">10.1002/mds.870040204</idno><idno type="ArticleID">MDS870040204</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>(+)‐4‐Propyl‐9‐hydroxynaphthoxazine</term><term>Administration, Cutaneous</term><term>Adult</term><term>Antiparkinson Agents (antagonists & inhibitors)</term><term>Antiparkinson Agents (pharmacokinetics)</term><term>Dopamine Antagonists</term><term>Dopamine agonist</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>On‐off fluctuations</term><term>Oxazines (administration & dosage)</term><term>Oxazines (pharmacokinetics)</term><term>Parkinson Disease (blood)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson's disease</term><term>Transdermal drug delivery</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Levodopa</term><term>Oxazines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Antiparkinson Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antiparkinson Agents</term><term>Oxazines</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Motor Skills</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Administration, Cutaneous</term><term>Adult</term><term>Dopamine Antagonists</term><term>Drug Administration Schedule</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Middle Aged</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">(+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO) is a potent dopamine agonist that has been administered transdermally to four patients with Parkinson's disease and “on‐off” fluctuations. Skin patches of increasing size were used to treat these patients, who also received infrequent doses of oral levodopa if required. The effect of +PHNO was measured as an increased duration of action of individual levodopa doses. The clinical effect measured in this way was directly proportional to the plasma concentrations of +PHNO achieved. The plasma concentrations of + PHNO began to rise 4–6 h after patch application and reached a steady state by 24 h. The final plasma concentration of + PHNO was proportional to the area of skin covered.</div></front></TEI><affiliations><list><country><li>Royaume-Uni</li><li>États-Unis</li></country><region><li>Angleterre</li><li>Grand Londres</li></region><settlement><li>Londres</li></settlement></list><tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Coleman" sort="Coleman" uniqKey="Coleman" last="Coleman">Coleman</name></region><name sortKey="Lange, K W" sort="Lange, K W" uniqKey="Lange K" first="K. W." last="Lange">K. W. Lange</name><name sortKey="Marsden, C D" sort="Marsden, C D" uniqKey="Marsden C" first="C. D." last="Marsden">C. D. Marsden</name><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><name sortKey="Quinn, N P" sort="Quinn, N P" uniqKey="Quinn N" first="N. P." last="Quinn">N. P. Quinn</name><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name></country><country name="États-Unis"><noRegion><name sortKey="Loper, A E" sort="Loper, A E" uniqKey="Loper A" first="A. E." last="Loper">A. E. Loper</name></noRegion><name sortKey="Bondi, J V" sort="Bondi, J V" uniqKey="Bondi J" first="J. V." last="Bondi">J. V. Bondi</name><name sortKey="Hichens, M" sort="Hichens, M" uniqKey="Hichens M" first="M." last="Hichens">M. Hichens</name><name sortKey="Stahl, S M" sort="Stahl, S M" uniqKey="Stahl S" first="S. M." last="Stahl">S. M. Stahl</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006424 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006424 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CDB145AA1E9A01CCC106745F8337B15DA7C6FA44
|texte= The antiparkinsonian actions and pharmacokinetics of transdermal (+)‐4‐Propyl‐9‐hydroxynaphthoxazine (+ PHNO): Preliminary results
}}
| This area was generated with Dilib version V0.6.23. |  |